---
title: "BETA: 146% revenue growth and expanded backlog highlight strong 2Q26 momentum and outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295646810.md"
description: "Revenue surged 146% year-over-year in 2Q26, with strong backlog growth and expanded charging infrastructure. Adjusted EBITDA loss widened due to increased R&D and launch costs, but liquidity remains robust. 2026 revenue guidance was raised, reflecting continued momentum.Original document: Beta Technologies, Inc. [BETA] Slides Release — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T10:07:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295646810.md)
  - [en](https://longbridge.com/en/news/295646810.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295646810.md)
generator: "portal-rs"
---

# BETA: 146% revenue growth and expanded backlog highlight strong 2Q26 momentum and outlook

Revenue surged 146% year-over-year in 2Q26, with strong backlog growth and expanded charging infrastructure. Adjusted EBITDA loss widened due to increased R&D and launch costs, but liquidity remains robust. 2026 revenue guidance was raised, reflecting continued momentum.

Original document: Beta Technologies, Inc. \[BETA\] Slides Release — Aug. 12 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [BETA.US](https://longbridge.com/en/quote/BETA.US.md)

## Related News & Research

- [Beta Technologies CEO Clark Kyle disposes of USD 2.12 million in common shares](https://longbridge.com/en/news/296653739.md)
- [Beta CEO Clark Kyle disposes of USD 1.96 million in Beta common shares](https://longbridge.com/en/news/296278104.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**